Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection

Norihiro Furusyo, Jun Hayashi, Misako Ohmiya, Yasunori Sawayama, Yasunobu Kawakami, Iwao Ariyama, Naoko Kinukawa, Seizaburo Kashiwagi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

To compare virological, biochemical, and immune responses to human lymphoblastoid interferon (IFN-α) and human fibroblast interferon (IFN-β) in patients with chronic hepatitis C virus (HCV) infection, 120 patients were randomly assigned to three groups (group A, 60 patients receiving IFN-α, 6 million units (MU) once a day, daily for one month and thrice weekly for five months; group B, 40 patients receiving 6 MU IFN-β once a day daily for two months; and group C, 20 patients receiving 3 MU IFN-β twice a day (6 MU/day) daily for two months). Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Patients with sustained clearance of serum HCV RNA detected by polymerase chain reaction (PCR) at six months after IFN treatment were defined as having complete response to IFN treatment. A low level of HCV RNA (≤104 copies/50 μl, measured by competitive PCR) and HCV RNA of genotype 2a were favorable factors for a complete response to both IFNs. Complete response in group A treatment was strongly associated with early HCV RNA clearance, in contrast with group B. A significantly higher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0%), compared with groups A (41.6%) and B (27.5%). sIL-2R levels rose in each group during IFN administration. In group C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findings indicate that timing of serum HCV RNA negativity in sustained response differs between IFN- α and IFN-β administrations and that early HCV RNA clearance was induced by twice-a-day IFN-β treatment.

Original languageEnglish
Pages (from-to)608-617
Number of pages10
JournalDigestive Diseases and Sciences
Volume44
Issue number3
DOIs
Publication statusPublished - Jan 1 1999

Fingerprint

Chronic Hepatitis C
Virus Diseases
Hepacivirus
Interferons
RNA
Interleukin-2 Receptors
Therapeutics
Interleukin-6
Serum
Polymerase Chain Reaction
Interferon-beta
DNA-Directed RNA Polymerases
Alanine Transaminase
Interferon-alpha
Enzyme-Linked Immunosorbent Assay
Genotype

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Furusyo, N., Hayashi, J., Ohmiya, M., Sawayama, Y., Kawakami, Y., Ariyama, I., ... Kashiwagi, S. (1999). Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection. Digestive Diseases and Sciences, 44(3), 608-617. https://doi.org/10.1023/A:1026625928117

Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection. / Furusyo, Norihiro; Hayashi, Jun; Ohmiya, Misako; Sawayama, Yasunori; Kawakami, Yasunobu; Ariyama, Iwao; Kinukawa, Naoko; Kashiwagi, Seizaburo.

In: Digestive Diseases and Sciences, Vol. 44, No. 3, 01.01.1999, p. 608-617.

Research output: Contribution to journalArticle

Furusyo, N, Hayashi, J, Ohmiya, M, Sawayama, Y, Kawakami, Y, Ariyama, I, Kinukawa, N & Kashiwagi, S 1999, 'Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection', Digestive Diseases and Sciences, vol. 44, no. 3, pp. 608-617. https://doi.org/10.1023/A:1026625928117
Furusyo, Norihiro ; Hayashi, Jun ; Ohmiya, Misako ; Sawayama, Yasunori ; Kawakami, Yasunobu ; Ariyama, Iwao ; Kinukawa, Naoko ; Kashiwagi, Seizaburo. / Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection. In: Digestive Diseases and Sciences. 1999 ; Vol. 44, No. 3. pp. 608-617.
@article{2e218f7860f34bf7b90ad634d2ec714c,
title = "Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection",
abstract = "To compare virological, biochemical, and immune responses to human lymphoblastoid interferon (IFN-α) and human fibroblast interferon (IFN-β) in patients with chronic hepatitis C virus (HCV) infection, 120 patients were randomly assigned to three groups (group A, 60 patients receiving IFN-α, 6 million units (MU) once a day, daily for one month and thrice weekly for five months; group B, 40 patients receiving 6 MU IFN-β once a day daily for two months; and group C, 20 patients receiving 3 MU IFN-β twice a day (6 MU/day) daily for two months). Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Patients with sustained clearance of serum HCV RNA detected by polymerase chain reaction (PCR) at six months after IFN treatment were defined as having complete response to IFN treatment. A low level of HCV RNA (≤104 copies/50 μl, measured by competitive PCR) and HCV RNA of genotype 2a were favorable factors for a complete response to both IFNs. Complete response in group A treatment was strongly associated with early HCV RNA clearance, in contrast with group B. A significantly higher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0{\%}), compared with groups A (41.6{\%}) and B (27.5{\%}). sIL-2R levels rose in each group during IFN administration. In group C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findings indicate that timing of serum HCV RNA negativity in sustained response differs between IFN- α and IFN-β administrations and that early HCV RNA clearance was induced by twice-a-day IFN-β treatment.",
author = "Norihiro Furusyo and Jun Hayashi and Misako Ohmiya and Yasunori Sawayama and Yasunobu Kawakami and Iwao Ariyama and Naoko Kinukawa and Seizaburo Kashiwagi",
year = "1999",
month = "1",
day = "1",
doi = "10.1023/A:1026625928117",
language = "English",
volume = "44",
pages = "608--617",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Differences between interferon-α and-β treatment for patients with chronic hepatitis C virus infection

AU - Furusyo, Norihiro

AU - Hayashi, Jun

AU - Ohmiya, Misako

AU - Sawayama, Yasunori

AU - Kawakami, Yasunobu

AU - Ariyama, Iwao

AU - Kinukawa, Naoko

AU - Kashiwagi, Seizaburo

PY - 1999/1/1

Y1 - 1999/1/1

N2 - To compare virological, biochemical, and immune responses to human lymphoblastoid interferon (IFN-α) and human fibroblast interferon (IFN-β) in patients with chronic hepatitis C virus (HCV) infection, 120 patients were randomly assigned to three groups (group A, 60 patients receiving IFN-α, 6 million units (MU) once a day, daily for one month and thrice weekly for five months; group B, 40 patients receiving 6 MU IFN-β once a day daily for two months; and group C, 20 patients receiving 3 MU IFN-β twice a day (6 MU/day) daily for two months). Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Patients with sustained clearance of serum HCV RNA detected by polymerase chain reaction (PCR) at six months after IFN treatment were defined as having complete response to IFN treatment. A low level of HCV RNA (≤104 copies/50 μl, measured by competitive PCR) and HCV RNA of genotype 2a were favorable factors for a complete response to both IFNs. Complete response in group A treatment was strongly associated with early HCV RNA clearance, in contrast with group B. A significantly higher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0%), compared with groups A (41.6%) and B (27.5%). sIL-2R levels rose in each group during IFN administration. In group C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findings indicate that timing of serum HCV RNA negativity in sustained response differs between IFN- α and IFN-β administrations and that early HCV RNA clearance was induced by twice-a-day IFN-β treatment.

AB - To compare virological, biochemical, and immune responses to human lymphoblastoid interferon (IFN-α) and human fibroblast interferon (IFN-β) in patients with chronic hepatitis C virus (HCV) infection, 120 patients were randomly assigned to three groups (group A, 60 patients receiving IFN-α, 6 million units (MU) once a day, daily for one month and thrice weekly for five months; group B, 40 patients receiving 6 MU IFN-β once a day daily for two months; and group C, 20 patients receiving 3 MU IFN-β twice a day (6 MU/day) daily for two months). Serum soluble interleukin-2 receptor (sIL-2R) and interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay. Patients with sustained clearance of serum HCV RNA detected by polymerase chain reaction (PCR) at six months after IFN treatment were defined as having complete response to IFN treatment. A low level of HCV RNA (≤104 copies/50 μl, measured by competitive PCR) and HCV RNA of genotype 2a were favorable factors for a complete response to both IFNs. Complete response in group A treatment was strongly associated with early HCV RNA clearance, in contrast with group B. A significantly higher HCV RNA negativity at the second week from start of treatment was noted in group C (80.0%), compared with groups A (41.6%) and B (27.5%). sIL-2R levels rose in each group during IFN administration. In group C, alanine aminotransferase (ALT) and IL-6 levels were remarkably elevated. These findings indicate that timing of serum HCV RNA negativity in sustained response differs between IFN- α and IFN-β administrations and that early HCV RNA clearance was induced by twice-a-day IFN-β treatment.

UR - http://www.scopus.com/inward/record.url?scp=0032987514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032987514&partnerID=8YFLogxK

U2 - 10.1023/A:1026625928117

DO - 10.1023/A:1026625928117

M3 - Article

VL - 44

SP - 608

EP - 617

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 3

ER -